Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Circulating histones as clinical biomarkers in critically ill conditions

  • García-Giménez, José Luis|||0000-0001-7547-7872
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Durá, Raquel
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
  • Bajaña, Iván
  • Bolado López de Andujar, David
  • Cánovas-Cervera, Irene|||0000-0001-9364-235X
  • Ceccato, Adrian|||0000-0001-9454-062X
  • Chiscano-Camón, Luis|||0000-0003-0037-0610
  • Climent Martinez, Elena
  • García Fernández, Georgia
  • Gomà, Gemma|||0000-0002-1890-4855
  • Monforte, Verónica
  • Quevedo, Beatriz
  • Ruiz-Sanmartin, Adolf
  • Sierra Rivera, Antonio
  • Carbonell, Nieves|||0000-0002-9149-0310
Extracellular histones, primarily nuclear proteins involved in chromatin organization, have emerged as key mediators in pathological processes in critically ill patients. When released into circulation due to cell death mechanisms such as NETosis, histones act as damage-associated molecular patterns (DAMPs), contributing to excessive inflammation, endothelial dysfunction, immune response dysregulation, coagulation activation, cell death, and multi-organ damage. Increasing evidence supports their role in the pathophysiology of sepsis, acute lung injury, cardiac injury, pancreatitis, and other life-threatening conditions. Given their strong association with disease severity and prognosis, circulating histones have gained attention as potential clinical biomarkers for early diagnosis, prognosis, and therapeutic monitoring in critically ill patients. This review discusses the biological roles of extracellular histones, their potential as biomarkers, different approaches to measure them, and emerging therapeutic strategies aimed at neutralizing or removing circulating histones to improve patient outcomes in severe medical conditions. {'boxed-text': {'@position': 'anchor', '@content-type': 'box', '@id': 'feb270093-blkfxd-0001', '@orientation': 'portrait', 'caption': {'title': 'Impact statement'}, 'p': 'This review highlights extracellular histones as key mediators and biomarkers in sepsis, proposing their use in diagnosis, prognosis, and treatment monitoring. Integrating quantitative proteomics for the detection of circulating histones may enhance patient stratification and guide therapeutic strategies, advancing personalized medicine in critical care.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease

  • Priego-Parra, Bryan Adrián
  • Gallego-Durán, Rocío
  • Román-Calleja, Berenice M.
  • Velarde-Ruiz Velasco, José Antonio
  • Romero-Gómez, Manuel
  • Gracia-Sancho, Jordi
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a pressing global health concern. The complexity of MASLD and the lack of universally effective treatments expose the limitations of current interventions, which focus mainly on lifestyle modifications. Here, we explore the multilayered nature of MASLD, emphasizing its pathophysiology in shaping future medical and lifestyle interventions from a personalized medicine perspective, based on individual molecular profiles. Additionally, we address the limitations of current animal models in reflecting human metabolic syndrome and sex-specific differences. We argue that a holistic approach, integrating social determinants of health, patient preferences, and adherence patterns, is essential for advancing MASLD management effectively., Authors acknowledge continuous funding from the Instituto de Salud Carlos III (ISCIII; currently PI23/00945, DTS22/00010 & DTS24/00035 to J.G.-S., CD21/00095, PI22/01342, PI22/01345 and PI24/02008 to R.G.-D. and M.R.-G., all co-funded by the European Union), the AGAUR-Generalitat de Catalunya (2021 SGR 01322 & 2021 PROD 00036) to J.G.-S and the CIBEREHD. CIBEREHD is funded by the Instituto de Salud Carlos III., Peer reviewed